Medpace Holdings, Inc. (NASDAQ:MEDP) Position Decreased by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. decreased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 13.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 39,461 shares of the company's stock after selling 6,012 shares during the period. Oppenheimer Asset Management Inc. owned about 0.13% of Medpace worth $13,110,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the stock. Iron Triangle Partners LP bought a new stake in Medpace during the third quarter valued at $64,371,000. Wellington Management Group LLP boosted its holdings in shares of Medpace by 36.0% in the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock valued at $138,612,000 after buying an additional 109,886 shares during the period. DF Dent & Co. Inc. grew its position in shares of Medpace by 189.9% during the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company's stock valued at $53,841,000 after buying an additional 105,659 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec acquired a new stake in Medpace during the third quarter worth about $23,321,000. Finally, Swedbank AB lifted its holdings in Medpace by 245.5% in the fourth quarter. Swedbank AB now owns 77,400 shares of the company's stock worth $25,715,000 after acquiring an additional 55,000 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Analysts Set New Price Targets

Separately, Robert W. Baird upped their target price on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a report on Monday, January 27th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $381.44.

Remove Ads

Medpace Price Performance

MEDP stock traded down $8.15 on Monday, reaching $319.17. The company's stock had a trading volume of 282,700 shares, compared to its average volume of 293,337. The firm has a fifty day moving average of $342.66 and a two-hundred day moving average of $345.16. The company has a market capitalization of $9.72 billion, a P/E ratio of 25.27, a price-to-earnings-growth ratio of 3.81 and a beta of 1.36. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.